A review of safety incidents in England and Wales for vascular endothelial growth factor inhibitor medications

Eye

Volumn 25, Issue 6, 2011, Pages 710-716

  Kelly, S P ^a   Barua, A ^a  

^a ROYAL BOLTON HOSPITAL   (United Kingdom)

Author keywords

endophthalmitis; macular; organization; patient safety incident; retina; vascular endothelial growth factor

Indexed keywords

BEVACIZUMAB; PEGAPTANIB; RANIBIZUMAB; VASCULOTROPIN INHIBITOR;

DISEASE SEVERITY; DRUG FATALITY; DRUG SAFETY; DRUG STORAGE; ENDOPHTHALMITIS; EYE CARE; EYE INFLAMMATION; FOLLOW UP; HEART INFARCTION; HUMAN; INCIDENT REPORT; MEDICATION ERROR; PATIENT SAFETY; RETINA MACULA DEGENERATION; RETROSPECTIVE STUDY; REVIEW; STROKE; SUBDURAL HEMATOMA; UNITED KINGDOM;

EID: 79958748965     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2011.89     Document Type: Review

References (40)

1. Owen CG, Fletcher AE, Donoghue M, Rudnicka AR. How big is the burden of visual loss caused by age related macular degeneration in the United Kingdom? Br J Ophthalmol 2003;87:312-317. (Pubitemid 36307906)
2. Bunce C, Xing W, Wormald R. Causes of blind and partial sight certifications in England and Wales: April 2007-March 2008. Eye 2010;24:1692-1699.
3. Gragoudas ES, Adamis AP, Cunningham Jr ET, Feinsod M, Guyer DR, for the VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-2816. (Pubitemid 40051904)
4. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-1431. (Pubitemid 44511557)
5. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY et al. Ranibizumab vs verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-1444. (Pubitemid 44511558)
6. Chakravarthy U, Soubrane G, Bandello F, Chong V, Creuzot-Garcher C, Dimitrakos II SA et al. Evolving European guidance on the medical management of neovascular age related macular degeneration. Br J Ophthalmol 2006;90:1188-1196. (Pubitemid 44351155)
7. Royal College of Ophthalmologists. Commissioning Contemporary AMD Services: a Guide for Commissioners and Clinicians. Royal College of Ophthalmologists: London, 2007. http://www.rcophth.ac.uk/documents.asp?section= 39§ionTitle=Publications&let=C&page=7.
8. National Institute for Health and Clinical Evidence. NICE Technology Appraisal Guidance TA155, Ranibizumab and Pegaptanib for the Treatment of Age-related Macular Degeneration. National Institute for Health and Clinical Evidence: London, 2008. http://www.nice.org.uk/nicemedia/pdf/TA155guidance.pdf.
9. Amoaku W. Ranibizumab: The clinician's guide to commencing, continuing, and discontinuing treatment. Eye 2009;23:2140-2142.
10. Royal College of Ophthalmologists. AMD Services Survey. Royal College of Ophthalmologists: London, 2009. http://www.rcophth.ac.uk/page.asp?section= 295§ionTitle=AMD+Services+Survey.
11. Bressler NM. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials. TAP report number 2. Arch Ophthalmol 2001;119:198-207. (Pubitemid 32147926)
12. Mitchell J, Bradley C. Quality of life in age-related macular degeneration: a review of the literature. HealthQual of Life Outcomes 2006;4:97.
13. World Health Organization. WHO Draft Guidelines on Adverse Event Reporting and Learning Systems. World Health Organization Press: Geneva, Switzerland, 2005. http://www.who.int/patientsafety/events/05/Reporting- Guidelines.pdf.
14. National Patient Safety Agency. Report a Patient Safety Incident Here. National Patient Safety Agency: London. http://www.npsa.nhs.uk/patientsafety/ reporting.
15. Department of Health. Review of Arm's Length Bodies to Cut Bureaucracy. Depart of Health: London, 2010. http://www.dh.gov. uk/en/MediaCentre/ Pressreleases/DH-117844.
16. Traquair H. Removal of the wrong eye. Br J Ophthalmol 1947;31:8-12.
17. Simon JW, Ngo Y, Khan S, Strogatz D. Surgical confusions in ophthalmology. Arch Ophthalmol 2007;125:1515-1522. (Pubitemid 350106684)
18. Dixon-Woods M. Why is patient safety so hard? A selective review of ethnographic studies. J Health Serv Res Policy 2010;15:11-16.
19. Vincent CN, Stanhope N, Crowley-Murphy M. Reasons for not reporting adverse incidents: an empirical study. J Eval Clin Pract 1999;5:13-21. (Pubitemid 29093010)
20. Lawton R, Parker D. Barriers to incident reporting in a healthcare system. Qual Saf Health Care 2002;11:15-18. (Pubitemid 35265296)
21. Evans SM, Berry JG, Smith BJ, Esterman A, Selim P, O'Shaughnessy J et al. Attitudes and barriers to incident reporting: a collaborative hospital study. Qual Saf Health Care 2006;15:39-43. (Pubitemid 43275524)
22. National Patient Safety Agency. Seven Steps to Patient Safety. National Patient Safety Agency: London, 2005. http://www.nrls.npsa.nhs.uk/resources/ collections/seven-steps-to-patient-safety.
23. Arnot-Smith J, Smith AF. Patient safety incidents involving neuromuscular blockade: analysis of the UK National Reporting and Learning System data from 2006 to 2008. Anaesthesia 2010;65:1106-1113.
24. Kelly SP, Jalil A. Wrong intraocular lens implant; learning from reported patient safety incidents. Eye 2011;25:730-734.
25. Scott IU, Flynn Jr HW. Reducing the risk of endophthalmitis following intravitreal injections. Retina 2007;27:10-12. (Pubitemid 46095824)
26. Fintak DR, Shah GK, Blinder KJ, Regillo CD, Pollack J, Heier JS et al. Incidence of endophthalmitis related to intravitreal injection of bevacizumab and ranibizumab. Retina 2008;28(10):1395-1399.
27. Mason III JO, White MF, Feist RM, Thomley ML, Albert MA, Persaud TO et al. Incidence of acute onset endophthalmitis following intravitreal bevacizumab (Avastin) injection. Retina 2008;28(4):564-567. (Pubitemid 351589565)
28. Pilli S, Kotsolis A, Spaide RF, Slakter J, Freund KB, Sorenson J et al. Endophthalmitis associated with intravitreal anti-vascular endothelial growth factor therapy injections in an office setting. Am J Ophthalmol 2008;145:879-882.
29. Johnson D, Hollands H, Hollands S, Sharma S. Incidence and characteristics of acute intraocular inflammation after intravitreal injection of bevacizumab: a retrospective cohort study. Can J Ophthalmol 2010;45:239-242.
30. McCannel CA. Meta-analysis of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents: Causative organisms and possible prevention strategies. Retina 2011;31:654-661.
31. Tey A, Lyall D, Foot B, Virdi M, Roxburgh S, MacEwan C. Post intravitreal anti-VEGF endophthalmitis (PIAE) in the United Kingdom: Incidence, Features and Outcomes, Conference Abstract; 24 May 2011. Royal College of Ophthalmologists Annual Scientific Congress: Birmingham.
32. Patient Safety First Campaign. Quick Guide to Briefing. Patient Safety First Campaign: London, 2010. Available at http://www.patientsafetyfirst.nhs.uk/ ashx/Asset.ashx?path=/Intervention-support/ Quick%20guide%20to%20briefngs%20and%20debriefings.pdf.
33. WHO Policy Perspectives on Medicines: World Health Organization. Looking at the Pharmacovigilance: Ensuring the Safe Use of Medicines. WHO: Geneva, 2004. Available from: http://whqlibdoc.who.int/hq/2004/WHO-EDM-2004.8.pdf.
34. Schmucker C, Ehlken C, Hansen LL, Antes G, Agostini HT, Lelgemann M. Intravitreal bevacizumab (Avastin) vs ranibizumab (Lucentis) for the treatment of age-related macular degeneration: a systematic review. Curr Opin Ophthalmol 2010;21:218-226.
35. Curtis LH, Hammill BG, Schulman KA, Cousins SW. Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration. Arch Ophthalmol 2010;128(10):1273-1279.
36. Fletcher AP. Spontaneous adverse drug reaction reporting vs event monitoring: a comparison. J R Soc Med 1991;84(6):341-344.
37. Massin P, Bandello F, Garweg JG, Hansen LL, Harding SP, Larsen M et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care 2010;33:2399-2405.
38. Karia N. Retinal vein occlusion: pathophysiology and treatment options. Clin Ophthalmol 2010;4:809-816.
39. The Royal College of Ophthalmologists. Retinal Vein Occlusion (RVO) Interim Guidelines. The Royal College of Ophthalmologists: London, 2010. http://www.rcophth.ac.uk/page.asp?section=451§ionTitle= Clinical+Guidelines.
40. The Royal College of Ophthalmologists. Patient Safety in Ophthalmology. The Royal College of Ophthalmologists: London, 2011. http://www.rcophth.ac.uk/ core/core-picker/download.asp?id=852&filetitle= Patient+Safety+in+Ophthalmology+February+2011.